Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

"Organon discontinues endometriosis drug after Phase II flunk" was originally created and published by Clinical Trials Arena, ...

AN endometriosis advocate has praised the government’s plan to establish a dedicated clinic in Jersey for those suffering from the debilitating reproductive condition. Kate Fry, founder of campaign ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Understand the causes of period pain, types of dysmenorrhea, and how diet, lifestyle, and expert treatment can help manage menstrual cramps and improve overall menstrual health.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A study found that a low FODMAP diet significantly reduced gastrointestinal symptoms such as abdominal pain and bloating in ...

New research links endometriosis to autoimmune diseases, revealing shared mechanisms that may lead to earlier diagnosis and ...

Endometriosis impacts daily functioning because of the intense cramps. Know how yoga may help support the pain.